Status:
TERMINATED
A Pharmacogenetic Investigation of Antipsychotics in Schizophrenia and Schizophrenia-Like Psychoses
Lead Sponsor:
TheraGenetics Limited
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
19-65 years
Brief Summary
An individual's genetic make-up is known to determine their response to antipsychotic medication. Genetic markers that determine efficacy and side effects of medication may be identified and used to p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Written informed consent must be obtained
- DSM-IV diagnosis must be one of:
- schizophrenia
- schizophreniform
- schizoaffective
- delusional disorder
- brief reactive psychosis
- psychosis not otherwise specified
- Ethnic origin of both parents must be known
- A minimum of 6 weeks continuous treatment completed with the given antipsychotic, prescribed at least at minimum recommended doses
- Prospectively collected outcome data available (pre-treatment and after at least 6 weeks on treatment)
- Exclusion criteria:
- Significant psychiatric or medical co-morbidity including history of:
- head injury with loss of consciousness
- seizures
- neurological disorder
- mental retardation (DSM-IV)
- drug or alcohol dependence (DSM-IV)
- serious physical illness e.g. malignancy, hepatic/renal insufficiency
- Concomitant psychotropic medication that may influence ratings
- Concomitant antipsychotics, antidepressants or mood stabilisers prescribed for \>2 weeks during the antipsychotic treatment period rated
Exclusion
Key Trial Info
Start Date :
May 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00701753
Start Date
May 1 2008
End Date
March 1 2009
Last Update
March 12 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver Coastal Health
Vancouver, British Columbia, Canada